Tag Archives: intellectual property

Genetic Technologies v. Bristol Myers – 101 At Work

Posted on November 5, 2014 by Warren Woessner

In the recent memorandum opinion, the court invalidated claim 1 of U.S. Pat. No. 5,612,179, owned by Genetic Technologies, Ltd., as “impermissibly [claiming] a natural phenomenon.” (Genetic Technologies, Ltd. v. Bristol-Myers Squibb Company, C.A. No. 12-394-LPS (D. Delaware, Oct. 30, … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | 1 Comment

Canadian Hospital To Travel The Long And Winding Road Of “Gene Patenting”

Posted on November 3, 2014 by Warren Woessner

Arguing that human DNA is a natural product, the Children’s Hospital of Eastern Ontario (CHEO) has filed suit in Federal Court to invalidate patents claiming human DNA or diagnostic methods that use it. It has been reported that CHEO was … Continue reading →

Posted in Canadian Practice | Tagged , , , , , , , , , , | Leave a comment

Section 101 at AIPLA

Posted on October 24, 2014 by Warren Woessner

The increasingly intense conversation about patentable subject matter post-Mayo, Myriad and Alice got off to a slow start at the “Partnering for Patents” meeting held at the PTO on Wednesday. The meeting was a scattering of in-house PTO reports and … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

EPO – New Guidance On Added Subject Matter

Posted on October 9, 2014 by Warren Woessner

A guest post from Paul Cole. Readers will be aware that added subject matter issues have for a long time been a thorny issue for EPO Examination practice. On 7 February 2014 a symposium on EPO practice regarding Art. 123(2) … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , | Leave a comment